View this email in your browser
Share Share
Tweet Tweet
Forward Forward

NICE News for Life Sciences

Bringing you our latest news, features and updates.
March 2022
Welcome to your new regular bulletin from NICE. Through this focused communication, we'll keep you informed about how we evaluate health technologies and work with the life sciences sector to enable improved patient access to the best treatments and care.


Pills in blister packs.

Improving patient access to innovative medicines

We've developed a new access forum tool for pharmaceutical developers interested in accessing the Innovative Licensing and Access Pathway. The pathway aims to streamline patient access to safe, financially sustainable and innovative medicines. The access forum tool will support developers in bringing innovative medicines to market. It will provide users with coordinated advice from a range of system stakeholders including NICE.

Magnifying glass with different types of health technologies within it.

Changes to how we evaluate health technologies

Following extensive consultation with industry, health system partners, healthcare professionals, academia and patients, we’re changing the way we evaluate medicines and other health technologies. The changes will give patients earlier access to innovative new treatments by allowing greater flexibility over decisions about value for money and consideration of a broader evidence base. 

Speech bubbles with question marks within them.

Medical technology and digital health developers – share your views

We'd like to hear from people working at or with medical technology and digital health companies to help inform our communications with you. Please complete a short 10-minute survey to share your perceptions and experiences of NICE. The survey will close at 5pm on Sunday 13 March 2022.

Take our quick survey

Expanding our scientific advice service

We’re expanding our scientific advisory service, NICE Scientific Advice, to better support companies whose products may require managed access to the NHS. We’ll do this by involving a managed access subject matter expert from within NICE to collaborate on your project. Managed access data collection has an important role to play in supporting earlier patient access to innovative treatments that have the potential to be cost-effective, but for which there is significant uncertainty around our decision to recommend a treatment for use.

In future, if companies seeking scientific advice from NICE have technical questions around data collection requirements as part of a future managed access arrangement, they should include these questions in their briefing book. This service is available for standard scientific advice and joint advice projects with the Medicines and Healthcare products Regulatory Agency. 

Contact NICE Scientific Advice for more information
NICE Talks logo.

Evidence standards framework for digital health technologies

In this episode of our NICE Talks podcast, Mark Salmon, programme director at NICE and Andrew Davies, digital health lead at the Association of British HealthTech Industries, discuss our evidence standards framework for digital health technologies. The framework helps developers and adopters of digital health technologies ensure new technologies are clinically effective and provide value for money.

Catch up on all our latest news


HeartFlow image.

Case study: HeartFlow's journey from NICE guidance to MedTech Funding Mandate

In this digital health case study, we chat with Gina McDonald Main and Campbell Rogers from HeartFlow. They reflect on their product’s journey through our Medical Technologies Evaluation Programme and provide advice for other medical technology companies considering submitting their product for NICE evaluation.


NICE methods technical workshop

Aimed at pharmaceutical companies and health economics and outcomes research consultancies, we are holding a technical workshop on recent changes to our health technology evaluation manual.

  • Tuesday 21 June 2022, 1pm to 5pm, through Zoom. 
This interactive session will include in-depth exploration and practical exercises on:
  • disease severity modifiers
  • real world evidence 
  • uncertainty.
Book your place


Toni Gasse

Putting user needs at the heart of our work

Toni Gasse, project manager at NICE, explains how user-needs are being placed front and centre to develop a multi-agency advisory service for developers and adopters of artificial intelligence and data-driven health technologies. 

Richard Chivers

Supporting digital health developers

Richard Chivers, operations manager at NICE, outlines how we’ve been supporting digital health technology developers who’ve been awarded funding from the Digital Health Technology Catalyst. He explains how we've been helping successful bid winners to determine the evidence required for NHS adoption.

Read more of our latest blog posts


Our new chief executive, Samantha Roberts.

New chief executive takes up her role

Last month, Dr Samantha Roberts joined NICE as our new chief executive. Dr Roberts is a qualified doctor with over 20 years’ experience of healthcare. Her previous roles include director of innovation, research and life sciences at NHS England and chief executive of the Accelerated Access Collaborative. 

Price increase for technology appraisals and highly specialised technologies

We are increasing our charges for technology and highly specialised technology evaluations. The updated fees will apply to evaluations with a formal start date (invitation to participate) on or after 1 April 2022. Small companies meeting the criteria will continue to receive a 75% discount.

View updated charges

unsubscribe from this list